Cargando…
Diffuse large B-cell lymphoma: 10 years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone
Treatment with rituximab plus a regimen of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) for patients with diffuse large B-cell lymphoma (DLBCL) has proven efficacy in clinical trials. The present study investigated its application in clinical practice. This single-center, retro...
Autores principales: | Horvat, Matej, Zadnik, Vesna, Južnič Šetina, Tanja, Boltežar, Lučka, Pahole Goličnik, Jana, Novaković, Srdjan, Jezeršek Novaković, Barbara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796369/ https://www.ncbi.nlm.nih.gov/pubmed/29467881 http://dx.doi.org/10.3892/ol.2018.7774 |
Ejemplares similares
-
Correlation of t(14;18) translocation breakpoint site with clinical characteristics in follicular lymphoma
por: Panjan, Matej, et al.
Publicado: (2023) -
Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma
por: Hornberger, John, et al.
Publicado: (2008) -
Limited efficacy of pixantrone in refractory diffuse large B-cell lymphoma
por: Novakovic, Aleksander, et al.
Publicado: (2020) -
Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma
por: Jezeršek Novaković, Barbara, et al.
Publicado: (2021) -
Gray zone lymphoma effectively treated with cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab chemotherapy: A case report
por: Hojo, Nobumasa, et al.
Publicado: (2022)